A host of British insurers have said they will not pay for treatment using a “miracle” weight loss jab, which launched in Britain today.
Aviva, Axa and WPA said they would not offer customers Novo Nordisk’s weight-loss drug Wegovy under their private medical insurance.
From today, some NHS patients could be prescribed the drug.
However, Aviva said: “Private medical insurance provides cover for acute conditions, that is disease, illness or injury that is likely to respond quickly to treatment.
“Treatment with Semaglutide, for diabetes or weight loss, is not a benefit under our policies.”
Axa also said it only covered acute illnesses, while WPA said it has a general exclusion on obesity.
Semaglutide is the active pharmaceutical ingredient in Wegovy and in Novo’s drug Ozempic, which…
